Skip to Content

Belumosudil FDA Approval Status

FDA Approved: No
Generic name: belumosudil
Company: Kadmon Holdings, Inc.
Treatment for: Graft-versus-host disease

Belumosudil (KD025) is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2) in development for the treatment of patients with chronic graft-versus-host disease (cGVHD).

Development Timeline for belumosudil

DateArticle
Sep 30, 2020Kadmon Announces Submission of New Drug Application to the U.S. FDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease
May 21, 2020Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.